A new study published in Nature introduces NK2R agonists as a promising alternative to GLP-1 drugs for obesity and diabetes, showing significant weight loss, improved glucose control, and no muscle loss in animal trials—potentially addressing key side effects and high costs associated with GLP-1 therapies like Ozempic and Wegovy, with human trials expected to begin next year.
Keep Reading
Add A Comment